TRMT11 is the catalytic subunit of the TRMT11-TRM112 methyltransferase complex that catalyzes S-adenosyl-L-methionine-dependent N(2)-methylation of guanosine at position 10 (m2G10) in tRNAs 1. This modification is one of the major tRNA guanine-N(2)-methylation events. TRMT11 operates in both cytoplasm and mitochondria, functioning as a key epitranscriptomic writer protein 2. Mechanistically, TRMT11-catalyzed m2G10 modifications enhance mRNA translation efficiency and are essential for optimal protein synthesis and cell proliferation 1. The enzyme is regulated allosterically by TRMT112 in a broader methyltransferase interactome. Clinically, TRMT11 dysregulation associates with multiple malignancies. Germline genetic variations in TRMT11 predict androgen deprivation therapy response in advanced prostate cancer, with rs1268121 and rs6900796 polymorphisms significantly affecting treatment failure times 3. TRMT11-GRIK2 fusion transcripts occur frequently across seven cancer types including breast, colon, lung, and liver cancers 456, with fusion transcript detection in blood showing potential as a biomarker. TRMT11 is also implicated in lower-grade glioma prognosis through mitochondrial RNA modification networks 7, and serves as an interacting partner in H3K36me3-regulated kidney cancer pathways 2.